DRREDDY2018-01-012018-03-31in-bse-fin:OneOperatingExpenses01Member DRREDDY2018-01-012018-03-31in-bse-fin:FourOperatingExpenses01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentRevenue01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentRevenue02Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentRevenue03Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentRevenue01Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentRevenue02Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentRevenue03Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentResults01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentResults02Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentResults03Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentResults01Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentResults02Member DRREDDY2018-01-012018-03-31in-bse-fin:FourReportableSegmentResults03Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentAssets01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentAssets02Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentAssets03Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentLiabilities01Member DRREDDY2018-03-31in-bse-fin:OneReportableSegmentLiabilities01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentLiabilities02Member DRREDDY2018-03-31in-bse-fin:OneReportableSegmentLiabilities02Member DRREDDY2018-01-012018-03-31in-bse-fin:OneReportableSegmentLiabilities03Member DRREDDY2018-03-31in-bse-fin:OneReportableSegmentLiabilities03Member DRREDDY2018-01-012018-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DRREDDY2018-01-012018-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DRREDDY2018-01-012018-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member DRREDDY2018-01-012018-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DRREDDY 2017-04-01 2018-03-31 2018-04-10 INR Millions Yearly Multi segment 2018-01-01 2018-03-31 Audited Standalone 24923000000.00 731000000.00 25654000000.00 5740000000.00 2146000000.00 -389000000.00 4633000000.00 140000000.00 1900000000.00 9529000000.00 23699000000.00 1955000000.00 0.00 1955000000.00 457000000.00 -269000000.00 188000000.00 0.00 1767000000.00 0.00 0.00 0.00 0.00 1767000000.00 -112000000.00 1655000000.00 1655000000.00 0.00 830000000.00 5 0 10.65 10.63 0.00 0.00 10.65 10.63 0.00 0.00 0.00 Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost. n nSegmental capital employed nAs certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table. n nNotes: n1. These results have been prepared on the basis of the audited financial statements for the year ended 31 March 2018 and the unaudited interim financial results upto the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015. n n2. Post implementation of Goods and Services Tax (“GST”) with effect from 1 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the year ended 31 March 2018 includes excise duty upto 30 June 2017. Accordingly, revenue from operations for the quarter and year ended 31 March 2018 are not comparable with those of the previous periods presented. n n3. The Company received a warning letter, dated 5 November 2015 from the U.S. FDA, regarding deviations with current Good Manufacturing Practices at its API manufacturing facilities in Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as regarding violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The Company submitted its response to the warning letter on 7 December 2015. The Company has provided an update to the U.S. FDA on the progress of remediation in January 2016, March 2016, May 2016 and August 2016. The U.S. FDA completed the reinspection of the aforementioned facilities in March and April 2017. The Company has responded to the observations identified by the U.S. FDA. The Company received Establishment Inspection report (EIR) from the U.S. FDA for API manufacturing facility at Miryalaguda in June 2017 which indicates that the audit is closed. With regard to the Oncology manufacturing facility at Duvvada and API manufacturing facility at Srikakulam, the Company received EIRs from the U.S. FDA in November 2017 and February 2018, respectively, which indicates that the status remains unchanged. n n4. The audited results have been reviewed by the Audit Committee of the Board on 21 May 2018 and approved by the Board of Directors of the Company at their meeting held on 22 May 2018. n n5. The Board of Directors, at their meeting held on 22 May 2017, have recommended a final dividend of Rs. 20 per share subject to the approval of shareholders. n n6. The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and not subjected to audit. n n7.The results for the quarter and year ended 31 March 2018 periods presented have been audited by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon. n 2017-04-01 2018-03-31 Audited Standalone 93593000000.00 2040000000.00 95633000000.00 20110000000.00 6716000000.00 -516000000.00 18430000000.00 628000000.00 7741000000.00 35554000000.00 88663000000.00 6970000000.00 0.00 6970000000.00 1381000000.00 -80000000.00 1301000000.00 0.00 5669000000.00 0.00 0.00 0.00 0.00 5669000000.00 -60000000.00 5609000000.00 5609000000.00 0.00 830000000.00 5 0 117248000000.00 34.19 34.12 0.00 0.00 34.19 34.12 0.00 0.00 0.00 Selling and other expenses 9529000000.00 Selling and other expenses 35554000000.00 Global Generics 20068000000.00 Pharmaceutical Services and Active Ingredients 6268000000.00 Proprietary Products 27000000.00 Global Generics 76150000000.00 Pharmaceutical Services and Active Ingredients 22741000000.00 Proprietary Products 109000000.00 26363000000.00 99000000000.00 1440000000.00 5407000000.00 24923000000.00 93593000000.00 Global Generics 3482000000.00 Pharmaceutical Services and Active Ingredients 383000000.00 Proprietary Products -841000000.00 Global Generics 11956000000.00 Pharmaceutical Services and Active Ingredients -3000000.00 Proprietary Products -3464000000.00 3024000000.00 8489000000.00 140000000.00 628000000.00 929000000.00 891000000.00 1955000000.00 6970000000.00 Global Generics 0.00 Pharmaceutical Services and Active Ingredients 0.00 Proprietary Products 0.00 0.00 0.00 0.00 Global Generics 0.00 Pharmaceutical Services and Active Ingredients 0.00 Proprietary Products 0.00 0.00 0.00 0.00 Global Generics includes operations of Biologics business. Inter-segment revenue represents sale from Pharmaceutical Services and Active Ingredients to Global Generics at cost. n nSegmental capital employed nAs certain assets of the Company including manufacturing facilities, development facilities and treasury assets and liabilities are often deployed interchangeably across segments, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table. n nNotes: n1. These results have been prepared on the basis of the audited financial statements for the year ended 31 March 2018 and the unaudited interim financial results upto the end of the third quarter, which are prepared in accordance with the Ind AS notified under the Companies (Indian Accounting Standards) Rules 2015. n n2. Post implementation of Goods and Services Tax (“GST”) with effect from 1 July 2017, revenue from operations is disclosed net of GST. Revenue from operations for the earlier periods included excise duty which is now subsumed in the GST. Revenue from operations for the year ended 31 March 2018 includes excise duty upto 30 June 2017. Accordingly, revenue from operations for the quarter and year ended 31 March 2018 are not comparable with those of the previous periods presented. n n3. The Company received a warning letter, dated 5 November 2015 from the U.S. FDA, regarding deviations with current Good Manufacturing Practices at its API manufacturing facilities in Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as regarding violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The Company submitted its response to the warning letter on 7 December 2015. The Company has provided an update to the U.S. FDA on the progress of remediation in January 2016, March 2016, May 2016 and August 2016. The U.S. FDA completed the reinspection of the aforementioned facilities in March and April 2017. The Company has responded to the observations identified by the U.S. FDA. The Company received Establishment Inspection report (EIR) from the U.S. FDA for API manufacturing facility at Miryalaguda in June 2017 which indicates that the audit is closed. With regard to the Oncology manufacturing facility at Duvvada and API manufacturing facility at Srikakulam, the Company received EIRs from the U.S. FDA in November 2017 and February 2018, respectively, which indicates that the status remains unchanged. n n4. The audited results have been reviewed by the Audit Committee of the Board on 21 May 2018 and approved by the Board of Directors of the Company at their meeting held on 22 May 2018. n n5. The Board of Directors, at their meeting held on 22 May 2017, have recommended a final dividend of Rs. 20 per share subject to the approval of shareholders. n n6. The figures of the fourth quarter are the balancing figures between audited figures in respect of the full financial year and published year to date figures upto the third quarter of the relevant financial year. Also the figures upto the end of third quarter were only reviewed and not subjected to audit. n n7.The results for the quarter and year ended 31 March 2018 periods presented have been audited by the Statutory Auditors of the Company. An unqualified report has been issued by them thereon. n